JUNSHI BIO Shares Climb Over 3% Following Earnings Report

Stock News04-28

JUNSHI BIO (01877) saw its shares rise more than 3% after the release of its financial results. At the time of writing, the stock was up 3.3%, trading at HK$26.94, with a turnover of HK$9.23 million. On April 27, the company announced that for the first quarter of 2026, its revenue reached approximately RMB 726 million, representing a year-on-year increase of 45.09%. The net loss attributable to shareholders was about RMB 20.564 million, narrowing by 91.24% compared to the same period last year. The basic loss per share was RMB 0.02. The growth in revenue during the reporting period was primarily driven by increased sales from commercialized drugs. Among these, the core product, toripalimab injection (brand name: Tuoyi®/LOQTORZI®, product code: JS001), generated domestic sales revenue of approximately RMB 623 million, up about 39.37% year-on-year. The company stated that the reduction in losses was mainly due to higher sales from commercialized drugs compared to the same period last year, as well as efforts to enhance R&D and sales efficiency under its "quality improvement and efficiency enhancement" initiative.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175032190?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175032190","market":"other","top_or_hot":-1,"title":"JUNSHI BIO Shares Climb Over 3% Following Earnings Report","media":"Stock News","content":"<p>JUNSHI BIO (01877) saw its shares rise more than 3% after the release of its financial results. At the time of writing, the stock was up 3.3%, trading at HK$26.94, with a turnover of HK$9.23 million. On April 27, the company announced that for the first quarter of 2026, its revenue reached approximately RMB 726 million, representing a year-on-year increase of 45.09%. The net loss attributable to shareholders was about RMB 20.564 million, narrowing by 91.24% compared to the same period last year. The basic loss per share was RMB 0.02. The growth in revenue during the reporting period was primarily driven by increased sales from commercialized drugs. Among these, the core product, toripalimab injection (brand name: Tuoyi®/LOQTORZI®, product code: JS001), generated domestic sales revenue of approximately RMB 623 million, up about 39.37% year-on-year. The company stated that the reduction in losses was mainly due to higher sales from commercialized drugs compared to the same period last year, as well as efforts to enhance R&D and sales efficiency under its \"quality improvement and efficiency enhancement\" initiative.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JUNSHI BIO Shares Climb Over 3% Following Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJUNSHI BIO Shares Climb Over 3% Following Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-28 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JUNSHI BIO (01877) saw its shares rise more than 3% after the release of its financial results. At the time of writing, the stock was up 3.3%, trading at HK$26.94, with a turnover of HK$9.23 million. On April 27, the company announced that for the first quarter of 2026, its revenue reached approximately RMB 726 million, representing a year-on-year increase of 45.09%. The net loss attributable to shareholders was about RMB 20.564 million, narrowing by 91.24% compared to the same period last year. The basic loss per share was RMB 0.02. The growth in revenue during the reporting period was primarily driven by increased sales from commercialized drugs. Among these, the core product, toripalimab injection (brand name: Tuoyi®/LOQTORZI®, product code: JS001), generated domestic sales revenue of approximately RMB 623 million, up about 39.37% year-on-year. The company stated that the reduction in losses was mainly due to higher sales from commercialized drugs compared to the same period last year, as well as efforts to enhance R&D and sales efficiency under its \"quality improvement and efficiency enhancement\" initiative.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1175032190","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175032190","pubTimestamp":1777340424,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JUNSHI BIO (01877) saw its shares rise more than 3% after the release of its financial results. At the time of writing, the stock was up 3.3%, trading at HK$26.94, with a turnover of HK$9.23 million....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","BK1583":"高瓴概念","VXUS":"国际股票ETF-Vanguard","BK0239":"医药制造","01877":"君实生物","BK4588":"碎股","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","BK1161":"生物科技"},"translate_title":"财报公布后君实生物股价上涨逾3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1,"VXUS":1},"content_text":"JUNSHI BIO (01877) saw its shares rise more than 3% after the release of its financial results. At the time of writing, the stock was up 3.3%, trading at HK$26.94, with a turnover of HK$9.23 million. On April 27, the company announced that for the first quarter of 2026, its revenue reached approximately RMB 726 million, representing a year-on-year increase of 45.09%. The net loss attributable to shareholders was about RMB 20.564 million, narrowing by 91.24% compared to the same period last year. The basic loss per share was RMB 0.02. The growth in revenue during the reporting period was primarily driven by increased sales from commercialized drugs. Among these, the core product, toripalimab injection (brand name: Tuoyi®/LOQTORZI®, product code: JS001), generated domestic sales revenue of approximately RMB 623 million, up about 39.37% year-on-year. The company stated that the reduction in losses was mainly due to higher sales from commercialized drugs compared to the same period last year, as well as efforts to enhance R&D and sales efficiency under its \"quality improvement and efficiency enhancement\" initiative.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175032190","isCrawlerRequest":true}